...
首页> 外文期刊>International Journal of Impotence Research >Feline penile erection induced by topical glans penis application of combination alprostadil and SEPA (Topiglan)
【24h】

Feline penile erection induced by topical glans penis application of combination alprostadil and SEPA (Topiglan)

机译:外用龟头阴茎引起的猫阴茎勃起联合前列地尔和SEPA的应用(Topiglan)

获取原文
           

摘要

The objective of this study was to evaluate the efficacy of topically applied prostaglandin E1 (PGE1)+5% SEPA (soft enhancement of percutaneous absorption) on the glans penis in a feline erection model. Erectile response after glans penis administration of PGE1+5% SEPA cream (Topiglan, MacroChem Co., Lexington, MA, USA) was compared to the erectile response after intracavernosal administration of the triple-drug combination (1.65mg papaverine, 25g phentolamine, and 0.5g PGE1). The placebo cream and increasing concentrations (0.25%, 2.5mg/ml; 0.5%, 5mg/ml; and 1%, 10mg/ml) of PGE1+5% SEPA were applied in a total volume of 0.1ml via a plastic needle-less syringe. The control triple-drug combination was administrated intracavernosally via a 30-gauge needle at the completion of each experiment to serve as a control reference. With each application of placebo, PGE1+SEPA, and the triple-drug combination, changes in intracavernosal pressure and systemic blood pressure were continuously monitored. Topical application of PGE1+SEPA induced increases in intracavernosal pressure in a dose-dependent manner, with minimal effects on systemic blood pressure. The increases obtained with 1% PGE1 Topiglan cream were similar to the intracavernosal pressure values elicited by the standard intracavernosal triple-drug combination. These data demonstrate that topical glans penis application of PGE1+SEPA can induce an erectile response in cats with minimal systemic adverse effects. Oral pharmacological agents are the first-line treatment for male ED. Studies investigating the effectiveness of noninvasive modalities such as topical therapy should continue, because these agents have the potential to avoid the systemic effects commonly seen with oral therapies. Additionally, topical therapy may also benefit patients who are unresponsive to oral agents or have explicit contraindications. Topical PGE1 application to the glans penis may become an important treatment option in selected patients suffering from erectile dysfunction.
机译:这项研究的目的是评估在猫勃起模型中局部应用前列腺素E1(PGE1)+ 5%SEPA(经皮吸收的软增强)的功效。将龟头阴茎注射PGE1 + 5%SEPA乳膏(Topiglan,MacroChem Co.,列克星敦,马萨诸塞州,美国)后的勃起反应与海绵体内鼻腔给药三联药物组合(1.65mg罂粟碱,25g酚妥拉明,和0.5g PGE1)。安慰剂乳膏和递增浓度(0.25%,2.5mg / ml; 0.5%,5mg / ml;和1%,10mg / ml)的PGE1 + 5%SEPA的总体积为0.1ml。塑料无针注射器。在每个实验完成时,通过30号针头经海绵体腔内给予对照三药组合,以作为对照参考。每次使用安慰剂,PGE1 + SEPA和三联药物组合时,都持续监测海绵体内的内压和全身性血压的变化。 PGE1 + SEPA的局部应用以剂量依赖的方式诱导了海绵体腔内压力的升高,对全身血压的影响最小。用1%PGE1 Topiglan乳膏获得的增加与标准海绵体内三联药物引起的海绵体内压力值相似。这些数据表明,PGE1 + SEPA的局部龟头阴茎应用可在猫中引起勃起反应,而全身副作用最小。口服药物是男性ED的一线治疗。应该继续研究无创疗法(例如局部疗法)的有效性的研究,因为这些药物具有避免口服疗法常见的全身效应的潜力。另外,局部治疗也可能有益于对口服药物无反应或有明确禁忌症的患者。在部分勃起功能障碍患者中,将PGE1局部应用在龟头上可能成为重要的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号